To reduce the use of Chemotherapy in elderly patients with ER-positive and HER2-positive breast cancer

IBCSG 55-17 TOUCH

Coordinating investigator

Dr. med.
Patrik
Weder
Kantonsspital St. Gallen
+41 71 494 18 80

Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer

For further information on the IBCSG 55-17 TOUCH trial, please consult the IBCSG website.

All trials